Lionello Marco, Blandamura Stella, Lovato Andrea, Franchella Sebastiano, Giacomelli Luciano, Ottaviano Giancarlo, Stellini Edoardo, Staffieri Alberto, Marioni Gino
Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy.
Acta Otolaryngol. 2013 Aug;133(8):874-80. doi: 10.3109/00016489.2013.777159. Epub 2013 Jun 14.
Nuclear nm23-H1 expression may be useful in identifying elderly patients operated for laryngeal squamous cell carcinoma (LSCC) at higher risk of recurrence. Further studies are needed to clarify the biological role of nm23-H1 in elderly patients with LSCC and to determine how to restore nm23-H1 loss of expression/function.
Nowadays more than 50% of cancer cases are elderly patients and this percentage is expected to be 70% by 2030. Despite advances in LSCC diagnosis and treatment, patient survival has not improved in the last two decades. Novel, effective strategies should rely also on receptor-mediated LSCC-targeted therapy. nm23-H1 protein is related to the tumor cells' metastatic potential, and low nm23-H1 expression in carcinomas often correlates with a poor prognosis.
Immunohistochemistry and image analysis were used to investigate the prognostic value of nm23-H1 expression and subcellular localization in a series of 54 elderly patients consecutively undergoing primary surgery for LSCC.
On univariate analysis, the disease recurrence rate correlated inversely with nuclear nm23-H1 expression (p = 0.014), and disease-free survival (DFS) was longer in patients whose nuclear nm23-H1 levels were ≥2.0% (p = 0.022). On multivariate analysis, nuclear nm23-H1 expression (hazard ratio (HR) 2.77, p = 0.022) and N stage (HR 3.49, p = 0.007) were prognostically significant in terms of DFS.
核nm23-H1表达可能有助于识别接受喉鳞状细胞癌(LSCC)手术的老年患者中复发风险较高者。需要进一步研究以阐明nm23-H1在老年LSCC患者中的生物学作用,并确定如何恢复nm23-H1表达/功能的缺失。
如今超过50%的癌症病例为老年患者,预计到2030年这一比例将达到70%。尽管LSCC的诊断和治疗取得了进展,但在过去二十年中患者生存率并未提高。新的有效策略也应依赖于受体介导的LSCC靶向治疗。nm23-H1蛋白与肿瘤细胞的转移潜能相关,癌组织中nm23-H1低表达通常与预后不良相关。
采用免疫组织化学和图像分析方法,对54例连续接受LSCC初次手术的老年患者系列研究nm23-H1表达和亚细胞定位的预后价值。
单因素分析显示,疾病复发率与核nm23-H1表达呈负相关(p = 0.014),核nm23-H1水平≥2.0%的患者无病生存期(DFS)更长(p = 0.022)。多因素分析显示,就DFS而言,核nm23-H1表达(风险比(HR)为2.77,p = 0.022)和N分期(HR为3.49,p = 0.007)具有预后意义。